TMX Newsfile Biotechnology News Releases

Defence Therapeutics Announces Grant of Restricted Stock Units

Fri, 24 Apr 2026 18:30:00 -0400

Montreal, Quebec--(Newsfile Corp. - April 24, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units ("RSUs") to Mr. Sebastien Plouffe, CEO and Director of the Company, vesting immediately. Each RSU entitles the holder thereof to receive one...

BYT Holdings Ltd. Announces Delay of Annual Filings and Application for a Management Cease Trade Order

Fri, 24 Apr 2026 14:28:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - BYT Holdings Ltd. (CSE: BYT) ("BYT" or the "Company") announces that it will require additional time to identify and appoint an external auditor registered in Canada to complete the audit for the Company's financial year ended December 31, 2025, including the 2024 comparative year, in accordance with the Canadian Generally Accepted Auditing Standards ("GAAS"). As a result, the Company will not be able to file its audited annual...

iSpecimen Announces 1-for-40 Reverse Stock Split

Fri, 24 Apr 2026 09:00:00 -0400

Woburn, Massachusetts--(Newsfile Corp. - April 24, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of...

Sernova Biotherapeutics Announces Closing of Recently Approved Financings

Thu, 23 Apr 2026 16:15:00 -0400

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced that it has completed the final closing of a series of previously disclosed financing transactions, following receipt of shareholder approval at the Company's...

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption

Thu, 23 Apr 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has surpassed 500,000 units sold from January 2023 through March 2026.This milestone reflects continued consumer adoption, repeat purchasing behavior, and steady brand development within the "better-for-you" food category. The Company...

Optimi Health Files LIFE Offering Document in Connection with NASDAQ Listing

Thu, 23 Apr 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 23, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that further to its press release dated March 16, 2026, it intends to complete a portion of its previously announced offering of common shares (the "Offering") in Canada pursuant to the Listed Issuer Financing Exemption contained in Part A of...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Thu, 23 Apr 2026 07:00:00 -0400

King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live...

Trenchant Technologies Capital Corp. Completes Unwinding of Previous Limitless Quantum Acquisition and Corporate Updates

Wed, 22 Apr 2026 08:30:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTCQB: AITTF) ("Trenchant" or the "Company") announces that it has completed the unwinding of the Company's acquisition of Limitless Quantum Computing Solutions Inc. ("Limitless Quantum") (collectively, the "Unwinding Transaction"), as previously announced on April 8, 2026.The Company has effectively cancelled the 10,000,000 common shares of the Company (the "Trenchant Shares") and...

Envoy Medical Reaches Critical Milestone in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant

Wed, 22 Apr 2026 08:00:00 -0400

White Bear Lake, Minnesota--(Newsfile Corp. - April 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that all 56 patients implanted and enrolled in its pivotal clinical trial evaluating the fully implanted Acclaim® cochlear implant have been through their "Activation Visits," when a patient's device is initially turned on for the first time. "The conclusion of our trial...

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio

Wed, 22 Apr 2026 06:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - April 22, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an operational update on its wholly owned subsidiary following the successful completion of its acquisition of Holy Crap Foods Inc.Since the closing of the transaction on February 27, 2026, Restart has been transitioning ownership and integrating portfolio operations under its leadership. The Company has...